Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from China Isotope & Radiation Corp. ( (HK:1763) ) is now available.
China Isotope & Radiation Corporation’s subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has submitted an IND application for its innovative BNCT boron drug, ‘Borofalan (10B) for Injection,’ which has been accepted by the National Medical Products Administration. This development marks a significant breakthrough in China’s BNCT technology, enhancing precision tumor treatment and contributing to global oncology advancements.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation (CIRC) is a company based in the People’s Republic of China, specializing in the development and production of isotopes and radiation-related products. It focuses on advancing medical technologies, particularly in the field of precision oncology.
Average Trading Volume: 297,498
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.13B
Find detailed analytics on 1763 stock on TipRanks’ Stock Analysis page.